|
|
|
|
|
|
|
|
|
|
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
CONCLUSIONS: Belinostat is well tolerated in both patient groups and shows some activity in patients with micropapillary (LMP) disease.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.